Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor ? antagonists-Reference-Cited by-同舟云学术

Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor ? antagonists

Published:2004 Issue:6 Volume:50 Page:1959-1966
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis & Rheumatism

Author:

Bergstrom Laurie,Yocum David E.,Ampel Neil M.,Villanueva Isidro,Lisse Jeffrey,Gluck Oscar,Tesser John,Posever James,Miller Margaret,Araujo Julio,Kageyama Dana M.,Berry Martin,Karl Linda,Yung Christianne M.

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference20 articles.

1. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

2. Questions and answers about Humira (adalimumab) for health care professionals [brochure]. Abbott Park, IL: Abbott Laboratories; 2003.

3. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor ? antagonists infliximab and etanercept

4. Coccidioidomycosis in Renal Replacement Therapy

Cited by 233 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Mycology Today: Emerging Challenges and Opportunities;Open Forum Infectious Diseases;2024-06-27

2. Low incidence of invasive fungal infection and risk factors in a large observational cohort of patients initiating tumor necrosis factor-alpha inhibitors for dermatologic conditions;Journal of the American Academy of Dermatology;2024-04

3. The Known and Unknown “Knowns” of Human Susceptibility to Coccidioidomycosis;Journal of Fungi;2024-03-28

4. Coccidioides Serologic Screening Practices in Individuals With Rheumatic and Autoimmune Diseases;ACR Open Rheumatology;2024-03-13

5. Risk of Coccidioidomycosis Infection Among Individuals Using Biologic Response Modifiers, Corticosteroids, and Oral Small Molecules;ACR Open Rheumatology;2024-02-29